
Lucid Diagnostics (LUCD) Stock Forecast & Price Target
Lucid Diagnostics (LUCD) Analyst Ratings
Bulls say
Lucid Diagnostics has demonstrated solid operational growth, with EsoGuard test volume increasing by 2% year-over-year in Q3 2025, suggesting a steady demand for its diagnostic services. The company's efforts to broaden coverage through private payers, employer-based plans, and its marketing initiatives, such as the #CheckYourFoodTube events, position it for expedited revenue growth, especially with anticipated enhancements to Medicare coverage. Furthermore, a successful MolDX CAC meeting has catalyzed increased engagement with Medicare, potentially unlocking significant revenue streams, which underscores the favorable valuation outlook for Lucid Diagnostics.
Bears say
Lucid Diagnostics Inc. reported disappointing revenue results in 3Q25, falling short of consensus estimates, which raises concerns about the company's ability to gain traction in a competitive market. Additionally, the decline in processed EsoGuard tests, dropping from previous quarters, signals potential challenges in the adoption and effectiveness of its product marketing strategies. The financial outlook is further complicated by significant risks related to liquidity, regulatory approvals, and reimbursement issues, which could hinder the company's growth and operational stability.
This aggregate rating is based on analysts' research of Lucid Diagnostics and is not a guaranteed prediction by Public.com or investment advice.
Lucid Diagnostics (LUCD) Analyst Forecast & Price Prediction
Start investing in Lucid Diagnostics (LUCD)
Order type
Buy in
Order amount
Est. shares
0 shares